The Food and Drug Administration on Tuesday approved Abon Pharmaceutical's clofarabine injection.
The drug is intended to treat pediatric patients 21 years and younger with acute lymphoblastic leukemia who've previously received at least two other treatments.
Clofarabine is the first generic version of Genzyme's Clolar injection, which had sales of $67 million in 2016, according to IMS data.
More articles on supply chain:
Viewpoint: Why healthcare needs more 'me too' drugs
FDA safety warning: Diabetes drug causes higher risk of foot, leg amputations
FDA pauses Concert Pharma's hair loss study: 4 things to know